Simcere’s Sanbexin Sublingual Tablets Added to China’s 2026 Reimbursement ListTip Ranks·Nov 15, 2026 at 11:13 PM02096-0.09%
HUTCHMED Announces Expanded Coverage on National Reimbursement Drug List for ELUNATE® and ORPATHYS® | HCM Stock NewsStockTitan·Nov 15, 2026 at 08:00 PMHCM+0.34%HAWG-0.44%
TUS-PHARMA: The net profit for the third quarter was 2.3495 million yuan, a year-on-year increase of 146.43%Zhitong·Oct 29, 2025 at 11:34 AM000590-0.77%
The change of control of TUS-PHARMA has been completed, and Hunan Sailuoxian has become the controlling shareholderZhitong·Sep 23, 2025 at 09:31 AM000590-0.77%
TUS-PHARMA plans to change its name to "GuHan Health Industry Group Co., Ltd."Zhitong·Sep 5, 2025 at 10:49 AM000590-0.77%
TUS-PHARMA: The 58.607 million shares held by the controlling shareholder are subject to judicial auction, and the company's control will change. TUS-PHARMA announced that on August 6, 2025, the company received the "Execution Ruling" from the Beijing Financial Court delivered by Hunan Sailoxian [Jing 74 Zhi 1019]Zhitong·Aug 8, 2025 at 12:29 PM000590-0.77%
TUS-PHARMA: Expected net profit loss of RMB 19 million to RMB 15 million in the first half of 2025Zhitong·Jul 14, 2025 at 09:30 AM000590-0.77%
Chinese medicine stocks opened higher, with TIBET AIM PHARM and ZHONGSHENGYAOYE both hitting the daily limit, followed by gains in JINGHUA PHARM, WOHUA PHARMACEUTICAL, TUS-PHARMA, and KANGHUI PHARMACEUTICALWallstreetcn·Jun 9, 2025 at 01:32 AM002317-4.05%002349-1.17%
TUS-PHARMA released its first-quarter performance, with a net loss attributable to the parent company of 16.2562 million yuanZhitong·Apr 27, 2025 at 09:01 AM000590-0.77%
TUS-PHARMA released its 2024 annual performance, turning from profit to a loss of 125 million yuanZhitong·Mar 27, 2025 at 01:23 PM000590-0.77%
National People's Congress representative Jiao Qisen: Suggests strengthening the overall layout of traditional Chinese medicine materials nationwideZhitong·Mar 4, 2025 at 11:28 AM000590-0.77%
TUS-PHARMA: The subsidiary Hengdao Pathology, in which it holds shares, assists Ruijin Hospital in collaborating with Huawei to launch the "Ruizhi Pathology Large Model."Zhitong·Feb 20, 2025 at 04:41 AM000590-0.77%
TUS-PHARMA issued a profit warning, expecting a net loss of 115 million to 149 million yuan for the fiscal year 2024, turning from profit to loss year-on-yearZhitong·Jan 24, 2025 at 03:11 PM000590-0.77%